Skip to main content
Premium Trial:

Request an Annual Quote

Sylentis Concludes Phase Ia Study of Glaucoma Drug

Premium

Sylentis announced this week that it has completed a phase Ia study of its siRNA-based glaucoma drug SYL040012.

The drug targets adrenergic receptor beta-2 and is delivered topically to the eye. Gene Silencing News first reported in April that the trial had been concluded and that SYL040012 proved to be both safe and well tolerated (GSN 4/1/2010).

This week, Sylentis said that the 30 healthy patients in the study showed "excellent local and systemic tolerance to SYL040012, leading to very positive trial results."

The company added that it will begin a phase I/II study in patients with elevated intraocular pressure "as soon as possible."

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.